Bluejay Diagnostics, Inc. Increase (Decrease) in Accounts Receivable
Bluejay Diagnostics, Inc. (BJDX) reported Increase (Decrease) in Accounts Receivable of -$645 for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2022-03-10
- Bluejay Diagnostics, Inc. increase (decrease) in accounts receivable for the quarter ending 2020-12-31 was $0.00.
- Bluejay Diagnostics, Inc. increase (decrease) in accounts receivable for fiscal 2020 was -$645.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$645.00 10-K · filed 2022-03-10 | |
| 2020-09-30 | -$645.00 10-Q · filed 2021-12-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |